Keywords: follow-up, data, phase, ii, trial, schering, ag
Follow-up data from a Phase II trial of Schering AG
Article | 24 May 2004
Follow-up data from a Phase II trial of Schering AG's Leukine (sargramostim) for the treatment of moderately-to-severely-active Crohn's disease, have ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
